ArticleNeurology2025

Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.

Scott D Newsome et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.